Monday, November 30, 2015

An aspirin a day keeps the neurologist away?

Aspirin, or acetylsalicylic acid, has been the most widely used medication across the globe for the past two centuries to prevent platelet aggregation and to treat symptoms of pain, fever, and inflammation. With so many pharmacological effects, researchers at Boyce Thompson Institute and John Hopkins University sought to identify all of aspirin’s actions. The primary metabolite of aspirin, salicylic acid (SA), was found to target several human proteins in a high-throughput screen of SA binding activity; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was one of the proteins discovered to be a target of SA.

GAPDH is well-known for facilitating the production of energy from glucose. In addition to catalyzing the sixth step of glycolysis, GAPDH has been implicated to aid in transcription activation, DNA repair, and more recently, to initiate apoptosis and cell death. GAPDH’s apoptotic actions affect multiple cell types, most interestingly neuronal cells in the presence of reactive oxygen species (ROS). GAPDH therefore is a major suspect in neurodegenerative diseases including Huntington’s, Parkinson’s, and Alzheimer’s diseases.

Under oxidative stress, such as in excess of the ROS nitric oxide and other reactive compounds, GAPDH enters the nucleus of a neuron where it then upregulates the transcription of inappropriate proteins. This distorted production of proteins initiates the apoptosis cascade, kills the cell, and eventually results in the neurodegeneration of the individual. SA, similarly to a current anti-Parkinson’s drug (deprenyl), prevents the modification of GAPDH that allows it to enter a neuron’s nucleus, thus preventing the downstream death of that neuron.

The suggested neuroprotective properties of SA led researchers to investigate additional compounds that have a greater affinity for GAPDH than aspirin-derived SA and found that SA in licorice, a Chinese medicinal herb, better binds GAPDH. Researchers are currently screening for even more potent forms of SA, anticipating that a stronger compound will exhibit greater ability to suppress GAPDH’s entry into neural nuclei and potentially arrest neurodegenerative diseases.

Here is a link to the study!
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0143447

No comments:

Post a Comment